ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer : pathology and molecular biology and early, advanced and recurrent disease
Copyright © 2024 European Society for Medical Oncology, European Society of Gynecological Oncology, European Society of Pathology. Published by Elsevier Ltd.. All rights reserved..
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 35(2024), 3 vom: 27. Feb., Seite 248-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ledermann, J A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2023.11.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367971852 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367971852 | ||
| 003 | DE-627 | ||
| 005 | 20240229155110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.11.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM367971852 | ||
| 035 | |a (NLM)38307807 | ||
| 035 | |a (PII)S0923-7534(23)05103-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ledermann, J A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer |b pathology and molecular biology and early, advanced and recurrent disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 European Society for Medical Oncology, European Society of Gynecological Oncology, European Society of Pathology. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a maintenance treatment | |
| 650 | 4 | |a molecular biology | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a surgery | |
| 700 | 1 | |a Matias-Guiu, X |e verfasserin |4 aut | |
| 700 | 1 | |a Amant, F |e verfasserin |4 aut | |
| 700 | 1 | |a Concin, N |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, B |e verfasserin |4 aut | |
| 700 | 1 | |a Fotopoulou, C |e verfasserin |4 aut | |
| 700 | 1 | |a González-Martin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gourley, C |e verfasserin |4 aut | |
| 700 | 1 | |a Leary, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lorusso, D |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chiva, L |e verfasserin |4 aut | |
| 700 | 1 | |a Cibula, D |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, N |e verfasserin |4 aut | |
| 700 | 1 | |a Croce, S |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Falandry, C |e verfasserin |4 aut | |
| 700 | 1 | |a Fischerova, D |e verfasserin |4 aut | |
| 700 | 1 | |a Harter, P |e verfasserin |4 aut | |
| 700 | 1 | |a Joly, F |e verfasserin |4 aut | |
| 700 | 1 | |a Lazaro, C |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, C |e verfasserin |4 aut | |
| 700 | 1 | |a Mahner, S |e verfasserin |4 aut | |
| 700 | 1 | |a Marmé, F |e verfasserin |4 aut | |
| 700 | 1 | |a Marth, C |e verfasserin |4 aut | |
| 700 | 1 | |a McCluggage, W G |e verfasserin |4 aut | |
| 700 | 1 | |a McNeish, I A |e verfasserin |4 aut | |
| 700 | 1 | |a Morice, P |e verfasserin |4 aut | |
| 700 | 1 | |a Nicum, S |e verfasserin |4 aut | |
| 700 | 1 | |a Oaknin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Fidalgo, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Pignata, S |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, P T |e verfasserin |4 aut | |
| 700 | 1 | |a Ray-Coquard, I |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, I |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, G |e verfasserin |4 aut | |
| 700 | 1 | |a Sehouli, J |e verfasserin |4 aut | |
| 700 | 1 | |a Shapira-Frommer, R |e verfasserin |4 aut | |
| 700 | 1 | |a Sundar, S |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, D S P |e verfasserin |4 aut | |
| 700 | 1 | |a Taskiran, C |e verfasserin |4 aut | |
| 700 | 1 | |a van Driel, W J |e verfasserin |4 aut | |
| 700 | 1 | |a Vergote, I |e verfasserin |4 aut | |
| 700 | 1 | |a Planchamp, F |e verfasserin |4 aut | |
| 700 | 1 | |a Sessa, C |e verfasserin |4 aut | |
| 700 | 1 | |a Fagotti, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 35(2024), 3 vom: 27. Feb., Seite 248-266 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:3 |g day:27 |g month:02 |g pages:248-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2023.11.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 3 |b 27 |c 02 |h 248-266 | ||